In the last two decades, the existence of key oncogenic alterations, such as activating mutations or chromosomal reorganization, has become crucial in the advanced stage non-small cell lung cancer (NSCLC) treatment paradigm. Among these, anaplastic lymphoma kinase (ALK) gene rearrangement is reported in 3-7% of NSCLC cases worldwide. In patients who respond to long-term ALK therapy, treatment duration is uncertain. The present study reported a case of variant type 1 ALK-rearranged stage 3B lung adenocarcinoma that maintained a complete response for >6 years under treatment with crizotinib. As first-line treatment, crizotinib was administered twice daily (250 mg) and a complete response was confirmed after 3 months. After a complete response to crizotinib for 6 years, the treatment was stopped and the patient was followed up. Multiple brain metastases were detected during the third month of follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.